Table 1.
Patient Demographics.
| Parameters | Medication Usage | All | ||||
|---|---|---|---|---|---|---|
| Statin | Omega-3 | |||||
| Yes (%) | No (%) | Yes (%) | No (%) | N | % | |
| Total Number of Patients | 42 (46.2%) | 49 (53.8%) | 28 (30.8%) | 63 (69.2%) | 91 | 100% |
| Age at Diagnosis (median(range)) | 66 (54–83)y | 67 (54–84)y | 65 (57–82)y | 68 (54–84)y | 67 (54–84)y | |
| Race | ||||||
| White | 85.7% | 85.7% | 82.1% | 87.3% | 78 | 85.7% |
| Non-White | 14.3% | 14.3% | 17.9% | 12.7% | 13 | 14.3% |
| Family History of Prostate Cancer | ||||||
| No | 78.6% | 75.5% | 75.0% | 76.2% | 70 | 76.9% |
| Yes | 21.4% | 24.5% | 25.0% | 23.8% | 21 | 23.1% |
| NCCN Risk Group | ||||||
| Low/Favorable Intermediate | 14.3% | 14.3% | 17.9% | 12.7% | 13 | 14.3% |
| Unfavorable Intermediate | 21.4% | 18.4% | 17.9% | 20.6% | 18 | 19.8% |
| High | 21.4% | 24.5% | 21.5% | 23.8% | 21 | 23.1% |
| Very High | 42.9% | 42.8% | 42.9% | 42.9% | 39 | 42.9% |
| Gleason Grade, Primary | ||||||
| 3 (4+3) | 40.5% | 38.8% | 42.9% | 38.1% | 36 | 39.6% |
| 4 (8) | 54.8% | 53.1% | 50.0% | 55.6% | 49 | 53.8% |
| 5 (9, 10) | 4.8% | 8.2% | 7.1% | 6.3% | 6 | 6.6% |
| Gleason Grade, Secondary | ||||||
| 3 (4+3) | 23.8% | 22.4% | 17.9% | 25.4% | 21 | 23.1% |
| 4 (8) | 23.8% | 24.5% | 28.6% | 22.2% | 22 | 24.2% |
| 5 (9, 10) | 52.4% | 53.1% | 53.6% | 52.4% | 48 | 52.8% |
| cT | ||||||
| cT1c | 26.2% | 26.5% | 21.4% | 28.6% | 24 | 26.4% |
| cT2 | ||||||
| cT2a | 16.7% | 18.4% | 21.5% | 16.0% | 16 | 17.6% |
| cT2b | 14.3% | 8.2% | 14.3% | 9.5% | 10 | 11.0% |
| cT2c | 7.1% | 10.2% | 10.7% | 7.9% | 8 | 8.8% |
| cT3 | 21.4% | 22.4% | 17.9% | 23.8% | 20 | 22.0% |
| cT3a | 14.3% | 14.3% | 14.3% | 14.3% | 13 | 14.3% |
| cT3b | ||||||
| cN | ||||||
| 0 | 88.1% | 85.7% | 82.1% | 88.9% | 79 | 86.8% |
| 1 | 11.9% | 14.3% | 17.9% | 11.1% | 12 | 13.2% |
| PSA | ||||||
| Pretreatment PSA (median(range)) | 9.69 (1.31–52.19) | 10.00 (1.39–59.99) | 10.73 (2.00–52.19) | 9.59(1.31–59.99) | 9.69 (1.31–59.99) | |